Mirati Therapeutics, Inc. Equity-NMS: MRTX

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$58.7

5Y :

-33%

What is the share price of Mirati Therapeutics, Inc. today?

Mirati Therapeutics, Inc. (MRTX) share price as of May 1, 2025, is $58.7. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Mirati Therapeutics, Inc.?

Yes, Indian Investors can invest in the Mirati Therapeutics, Inc. (MRTX) Share by opening an international trading account with Angel One.

How can I purchase Mirati Therapeutics, Inc. shares in India?

Purchasing Mirati Therapeutics, Inc. (MRTX) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Mirati Therapeutics, Inc. (MRTX) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Mirati Therapeutics, Inc.?

Yes, you can purchase fractional shares of Mirati Therapeutics, Inc. (MRTX) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Mirati Therapeutics, Inc.?

The market capitalization of Mirati Therapeutics, Inc. on May 1, 2025, is $0.

In which sector Mirati Therapeutics, Inc. belongs?

Mirati Therapeutics, Inc. operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Mirati Therapeutics, Inc. stocks?

In order to invest in Mirati Therapeutics, Inc. (MRTX) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Mirati Therapeutics, Inc. is a commercial-stage oncology company. The Company is developing novel therapeutics to address the genetic and immunological promoters of cancer. The Company's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.